Day: August 9, 2024

TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. (CTOR) New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) — On August 7, 2024, TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) (“TenX”), a publicly traded special purpose acquisition company, was notified by The Nasdaq Stock Market that trading in TenX’s securities had been halted for “additional information requested” from the company. The trading halt was imposed following volatility in the trading price and volume of TenX’s securities on Wednesday, August 7, 2024. TenX and its advisors have been in contact with representatives of Nasdaq regarding the lifting of the trading halt. While the trading halt is...

Proceeds will be used to execute contracts with the Indonesian government, U.S. Air Force and other clients NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES ORDISSEMINATION IN THE UNITED STATES DENVER, Aug. 09, 2024 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today announced that it closed the third and final tranche of its previously announced offering (the “Offering”) of Class “A” common shares of the Company. The third tranche included the issuance of 2,491,568 Common Shares at a price of CAD$0.45 per Common Share for aggregate gross proceeds of approximately CAD$1,121,206. Patrick A. Blott, Chairman and CEO of Intermap acquired approximately 6% of the Common Shares issued under the third tranche of the Offering. The...

BEDFORD, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to four newly hired employees. The awards were made as inducements material to each individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards to the four newly hired employees were granted effective as of August 5, 2024 and consist of (i) non-statutory stock options to purchase up to an aggregate of 132,400 shares of Ocular’s common stock at a per share exercise...

Series  RIKB 27 0415 RIKB 42 0217Settlement Date  08/14/2024 08/14/2024Total Amount Allocated (MM)  4,915 2,695All Bids Awarded At (Price / Yield)  98.980 / 8.410 78.730 / 6.580Total Number of Bids Received  35 26Total Amount of All Bids Received (MM)  7,465 5,145Total Number of Successful Bids  22 15Number of Bids Allocated in Full  22 15Lowest Price / Highest Yield Allocated  98.980 / 8.410 78.730 / 6.580Highest Price / Lowest Yield Allocated  99.050 / 8.380 79.000 / 6.550Lowest Price / Highest Yield Allocated in Full  98.980 / 8.410 78.730 / 6.580Weighted Average of Successful Bids (Price/Yield)  99.000 / 8.400 78.842 / 6.560Best Bid (Price / Yield)  99.050 / 8.380 79.000 / 6.550Worst Bid (Price / Yield)  98.869 / 8.460 78.450 / 6.610Weighted Average of All Bids Received (Price / Yield)  98.980 / 8.410 78.715 / 6.580Percentage...

Saskatoon, SK., Aug. 09, 2024 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, announced today that it will host a shareholder update call on August 13th, 2024 at 5:30pm EST. Draganfly CEO Cameron Chell will facilitate the shareholder update call and review the Company’s milestones. CFO Paul Sun will review the Company’s financial results for Q2 2024, which are planned to be filed after the market on August 13th, 2024. The Company will answer pre-submitted questions. Registration for the call can be done here. Investors are asked to submit their questions to investor.relations@draganfly.com. About Draganfly Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A) is the creator of quality, cutting-edge drone...

Toronto, ON, Canada, Aug. 09, 2024 (GLOBE NEWSWIRE) — Canada Carbon Inc. (the “Company”) (TSX-V:CCB), (FF:U7N1) reports that it has completed the first phase of a Bulk Sample Program for its 100% owned Asbury Graphite Project located 80 kilometers (“km”) NNE of Gatineau, near Notre-Dame-du-Laus, Québec. Working with SGS Lakefield, the Company completed work in the following critical areas:Head assays Bond Ball Work Index Analysis Two Flotation Tests (F01 and F02)Head AssaysThree samples were received: BK1 – high grade drill core, BK2 – low grade drill core, and BK3 – outcrop. These samples were prepared for testing, and a composite of the two drill core samples (BK1 and BK2) was prepared and named Core Comp.  Carbon speciation analyses of these samples shows total carbon ranging from 1.71% to 7.60% from low to high grade drill...

$426.4M cash, cash equivalents and marketable securities as of June 30, 2024;Projected cash runway into mid-2026 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the quarter ended June 30, 2024, and highlighted recent corporate accomplishments. “While we faced challenges this quarter with regards to the ongoing partial clinical hold on azenosertib, we remain steadfast in our confidence in the program’s therapeutic potential and in our commitment to bringing this investigational medicine to patients with gynecological malignancies,” said Kimberly Blackwell, M.D., Chief...